Feb 23, 2023 7:30am EST 180 Life Sciences Announces Allowance of Claims for a US Patent for Dupuytren’s Disease Treatment and Application
Jan 25, 2023 8:45am EST 180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren’s Disease
Jan 17, 2023 8:00am EST 180 Life Sciences Engages Kinexum for Assistance in Applying for Marketing Authorisation in the United Kingdom
Jan 05, 2023 8:30am EST 180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
Jan 04, 2023 8:30am EST 180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren’s Disease
Dec 29, 2022 8:30am EST 180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders
Dec 23, 2022 8:00am EST 180 Life Sciences Corp. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Dec 20, 2022 2:11pm EST 180 Life Sciences Corp. Announces $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Dec 16, 2022 9:00am EST 180 Life Sciences Corp. Announces 1-for 20 Reverse Stock Split as Part of Nasdaq Compliance Plan